Obstetric and Gynecologic Imaging

Should You Order an Ultrasound for Ovarian Cancer Screening in Average-Risk Premenopausal Women?

·
Should You Order an Ultrasound for Ovarian Cancer Screening in Average-Risk Premenopausal Women?

A 38-year-old G2P2 woman presents for her annual wellness visit. She has no personal or family history of gynecologic malignancy but has seen commercials about ovarian cancer and asks if she should get a “screening ultrasound” to be safe. She is asymptomatic and has regular menses. You consider ordering a pelvic ultrasound to reassure her, but pause to consider the evidence and potential for unintended consequences. This article addresses the specific American College of Radiology (ACR) guidelines for this exact clinical question: ovarian cancer screening in an average-risk, premenopausal adult. For this patient, imaging such as `US color Doppler ovaries` is rated as `Usually not appropriate`.

Who Fits This Clinical Scenario?

This guidance applies specifically to asymptomatic, premenopausal adults at average risk for ovarian cancer. Defining these terms is critical to applying the recommendations correctly.

  • Premenopausal Status: This includes individuals who are still having menstrual cycles and have not entered menopause. The hormonal milieu and high prevalence of benign, functional ovarian cysts in this group are key factors influencing screening recommendations.
    • Average Risk: This is defined by the absence of known high-risk factors. A patient is not average-risk if they have a known pathogenic or likely pathogenic genetic mutation (e.g., BRCA1, BRCA2), a strong family history suggestive of a hereditary cancer syndrome (like Lynch syndrome or hereditary breast and ovarian cancer syndrome), or a personal history of certain cancers.

This workflow is not for patients who are postmenopausal, as their baseline risk and the significance of an adnexal finding are different. It also does not apply to any patient, premenopausal or not, who is considered high-risk. Those scenarios represent distinct clinical questions with different ACR recommendations. Finally, this guidance is for screening in an asymptomatic patient, not for the diagnostic workup of a patient with symptoms like pelvic pain, bloating, or a palpable mass.

What Diagnoses Are You Working Up in This Scenario?

In a screening context, the primary goal is to detect a disease before it becomes symptomatic. However, the practical challenge is distinguishing the target disease from benign mimics, which are far more common. The “differential” in this scenario is less about a patient’s symptoms and more about the potential findings on an ultrasound and their clinical significance.

Benign Functional Ovarian Cysts: This is overwhelmingly the most common finding on a pelvic ultrasound in a premenopausal woman. Follicular cysts and corpus luteum cysts are a normal part of the ovulatory cycle. Imaging in this population has a very high probability of detecting these physiologic structures, which can trigger anxiety and lead to unnecessary follow-up imaging or interventions, despite being harmless and self-resolving.

Other Benign Adnexal Lesions: Less common than functional cysts but still far more prevalent than cancer, other benign findings include endometriomas, hemorrhagic cysts, or mature cystic teratomas (dermoids). While these may sometimes warrant monitoring or treatment, they are not the target of a cancer screening program, and their incidental discovery contributes to the high false-positive rate of screening.

Early-Stage Ovarian Cancer: This is the theoretical target of screening. The hope is to identify epithelial ovarian cancer at Stage I or II, when it is most treatable. However, due to the very low prevalence of ovarian cancer in the average-risk premenopausal population, the vast majority of abnormal findings on a screening ultrasound will not be cancer. The positive predictive value of an abnormal ultrasound for malignancy in this setting is extremely low.

Why Is No Imaging Study Recommended for This Presentation?

The ACR Appropriateness Criteria panel, in alignment with major gynecologic and preventative medicine societies, rates all imaging modalities, including `US color Doppler ovaries`, as `Usually not appropriate` for ovarian cancer screening in this population. The rationale is not that imaging cannot detect ovarian abnormalities, but that a screening program using these tools causes more harm than good.

The core issue is the combination of low disease prevalence and the low specificity of imaging. Ovarian cancer is relatively uncommon in the general population, particularly among premenopausal women. Meanwhile, pelvic ultrasound frequently identifies benign cysts and other non-cancerous findings. This imbalance leads to a high number of false-positive results. Major clinical trials have demonstrated that screening average-risk women with ultrasound and/or serum CA-125 does not lead to a reduction in ovarian cancer mortality. Instead, it leads to a significant number of unnecessary surgeries, including oophorectomies in women who never had cancer, with associated surgical risks and potential for premature menopause.

Alternative imaging modalities fare no better and introduce other disadvantages:

  • CT of the Abdomen and Pelvis: This is also rated `Usually not appropriate`. It offers no sensitivity advantage over ultrasound for early-stage ovarian cancer and exposes the patient to ionizing radiation (1-10 mSv for a standard protocol). Its primary role is in staging confirmed cancer, not screening.
  • MRI of the Pelvis: While excellent for characterizing an indeterminate adnexal mass found incidentally or during a diagnostic workup, MRI is rated `Usually not appropriate` for screening. It is more expensive, less accessible, and still subject to false positives from benign lesions.

The consensus is clear: the harms of screening this population—including patient anxiety, costly workups, and surgical complications from false-positive findings—outweigh the potential benefits. The focus should be on risk assessment and patient education, not routine imaging.

What’s Next? The Downstream Workflow Without Imaging

Since the recommended step is to avoid imaging, the downstream workflow focuses on patient counseling, risk assessment, and symptom awareness. The conversation with the patient is the most critical intervention.

  • If No Imaging Is Performed (Recommended Path): The next step is to educate the patient. Explain that major medical organizations do not recommend routine ovarian cancer screening for average-risk women because studies show it leads to unnecessary surgeries without saving lives. Reassure her that her risk is low. Shift the focus to symptom awareness, counseling her to report persistent and new-onset symptoms like bloating, pelvic or abdominal pain, difficulty eating, or urinary urgency. Re-evaluate her family history periodically to ensure she remains in the average-risk category.
  • If Imaging Is Inappropriately Ordered and Is Negative: Provide reassurance, but use it as a teaching moment. Explain that a single negative ultrasound does not guarantee she will never develop cancer and that repeated screening is not recommended.
  • If Imaging Is Inappropriately Ordered and Is Positive: The patient has now been shifted from a “screening” pathway to a “diagnostic” one. A simple cyst <5 cm in a premenopausal woman is almost always benign and requires no follow-up. A larger or complex-appearing cyst may require short-interval follow-up ultrasound or referral to gynecology. This initiates the very cascade of interventions that screening aims to avoid. The workup would then follow a different ACR topic, such as the one for a clinically suspected adnexal mass.

Pitfalls to Avoid (and When to Get Help)

The primary pitfall in this scenario is yielding to patient request or personal habit by ordering a screening ultrasound against evidence-based guidelines. This can initiate a cascade of iatrogenic harm. Another common error is misclassifying a patient’s risk; a thorough family history is essential to ensure an apparently average-risk patient does not actually meet criteria for high-risk surveillance. Do not confuse screening an asymptomatic patient with evaluating a symptomatic one; if the patient has persistent pelvic pain or bloating, a diagnostic ultrasound is appropriate, but that is a different clinical question. If you are uncertain about a patient’s risk based on a complex family history, escalate by referring them to a gynecologist or a genetic counselor for formal risk assessment.

Related ACR Topics and Tools

Navigating imaging guidelines requires staying current with the evidence and understanding the nuances of different clinical scenarios. For a broader overview of all patient populations for this topic, or to explore the tools used to make these decisions, the following resources are helpful:

Frequently Asked Questions

Why is ovarian cancer screening not recommended for average-risk premenopausal women when it is for other cancers like breast or cervical cancer?

The key difference lies in the ‘benefit-to-harm’ ratio. For breast and cervical cancer, we have screening tests (mammography, Pap/HPV tests) that have been proven in large trials to reduce mortality from the disease. For ovarian cancer in average-risk women, no current screening method (ultrasound or CA-125) has been shown to reduce mortality, but they have been shown to cause significant harm through false-positive results leading to unnecessary surgeries.

If my patient insists on an ultrasound for peace of mind, should I order it?

This is a common clinical challenge. The evidence-based recommendation is to avoid ordering the test. The best approach is a thorough conversation explaining why it’s not recommended, focusing on the high likelihood of false positives and the potential for a cascade of interventions, including surgery, for benign findings. Ordering a test against guidelines for reassurance can often lead to more anxiety, not less.

What if the patient has a family history of breast cancer but not ovarian cancer?

This requires careful evaluation. A single relative with postmenopausal breast cancer may not significantly increase her ovarian cancer risk. However, a family history of premenopausal breast cancer, male breast cancer, or multiple relatives with breast cancer could suggest a hereditary syndrome (like BRCA) that would place her in a high-risk category. A detailed three-generation pedigree is needed, and if there is any concern, referral for genetic counseling is the appropriate next step, not ordering a screening ultrasound.

Does this ‘no screening’ recommendation change if the patient is on oral contraceptives?

No, the recommendation to avoid screening does not change. In fact, long-term use of combined oral contraceptives is known to be protective and significantly reduces a woman’s lifetime risk of developing ovarian cancer. Her risk would be even lower than that of the general average-risk population, further strengthening the argument against screening.

What are the specific symptoms I should counsel my patient to watch for?

Unlike the historical notion of a ‘silent killer,’ ovarian cancer often does have symptoms, but they can be vague. Counsel her to seek medical attention for new and persistent (occurring most days for more than a few weeks) symptoms such as: bloating, pelvic or abdominal pain, feeling full quickly or difficulty eating, and urinary symptoms like urgency or frequency. The key is the persistent and new nature of these symptoms.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026